Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Rapid Flu Tests in Travelers With Fever
This study is currently recruiting participants.
Verified by University of Lausanne Hospitals, January 2009
Sponsored by: University of Lausanne Hospitals
Information provided by: University of Lausanne Hospitals
ClinicalTrials.gov Identifier: NCT00821626
  Purpose

Influenza is a frequent cause of fever in returning travelers. Usually diagnosis rests on the clinical picture. Rapid flu tests are becoming increasingly popular, although their sensitivity and specificity are suboptimal. The objective of this study is to evaluate if rapid flu tests influence the medical management of returning travelers with fever, a population at intermediate risk for influenza infections.


Condition Intervention Phase
Influenza
Device: BD Directigen EZ Flu A+B
Other: Control
Phase IV

MedlinePlus related topics: Fever Flu
U.S. FDA Resources
Study Type: Interventional
Study Design: Diagnostic, Randomized, Open Label, Uncontrolled, Parallel Assignment
Official Title: Utility of Rapid Flu Tests in the Medical Management of Returning Travelers With Fever

Further study details as provided by University of Lausanne Hospitals:

Primary Outcome Measures:
  • Difference in utilization of diagnostic tests and anti-infective drugs between the group with rapid flu test and the group without flu test [ Time Frame: 2 years ] [ Designated as safety issue: No ]

Estimated Enrollment: 450
Study Start Date: January 2009
Estimated Study Completion Date: June 2011
Estimated Primary Completion Date: December 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Rapid test: Active Comparator
Returning travelers with fever will have a rapid flu test
Device: BD Directigen EZ Flu A+B
Naso-pharyngeal swab and rapid flu test
Comparator: Sham Comparator
Returning travelers with fever will benefit of the usual medical care, without rapid flu test
Other: Control
No rapid flu test

Detailed Description:

Travelers are at risk of acquiring infectious diseases. Previous studies have estimated that about 11% of travelers develop fever during or shortly after their trip abroad. Influenza has been shown to be one of the most important cause of fever amongst travelers. A sero-epidemiological survey showed that 27 of 211 patients (12.8%) with fever during or after a trip abroad developed antibodies against the influenza virus. Another study showed that 13% of travellers, who consulted after return with flu-like symptoms, had PCR or culture-proven influenza. The incidence of influenza in travellers varies according to the seasons, but cases can be seen year round. In tropical countries transmission is year-long and in the southern hemisphere the flu epidemics occur during the summer of the northern hemisphere.

In most hospitals no confirmatory test for influenza is routinely done. For special cases a PCR or viral culture can be requested, but the results are only available after 48 hours for the PCR and after several days for the culture. It is suspected that the inability to confirm the diagnosis of flu contributes to the request of a greater number of useless investigations and inappropriate use of anti-infective treatments.

Rapid diagnostic tests are easy to use, relatively cheap and they yield a result within a clinically relevant time frame (30 minutes). For the detection of influenza there are a variety of rapid diagnostic tests on the market. The reported sensitivities and specificities are quite variable, but the new generations report median sensitivities of 70 - 75% and median specificities between 90 and 95%. The rapid tests are considered most useful in patient populations with a significant proportion of influenza cases. The WHO encourages to use rapid diagnostic tests for influenza in returning travelers with fever, considering that this patient population is at significant risk of acquiring influenza during their trip.

The aim of this study is to evaluate if rapid flu tests influence the medical management of returning travelers with fever

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Adults 18 years or older
  • Returning from abroad within the last 14 days
  • Documented fever of 38oC or above or anamnestic fever + cough or sore throat within the last 4 days before the consultation.

Exclusion Criteria:

  • Unwillingness to participate
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00821626

Contacts
Contact: Serge de Valliere, MD, Msc +41 21 314 48 52 serge.de-valliere@hospvd.ch

Locations
Switzerland
Medical outpatient clinic, University Hospital of Lausanne Recruiting
Lausanne, Switzerland, 1011
Contact: Serge de Valliere, MD     +41 21 314 48 52     serge.de-valliere@hospvd.ch    
Sub-Investigator: Philippe Staeger, MD            
Sub-Investigator: Pascal Meylan, MD            
Sub-Investigator: Blaise Genton, MD            
Principal Investigator: Serge de Valliere, MD            
Tropical Institute Basel Recruiting
Basel, Switzerland, 4002
Contact: Christoph Hatz, MD         christoph.hatz@unibas.ch    
Principal Investigator: Christoph Hatz, MD            
Sponsors and Collaborators
University of Lausanne Hospitals
Investigators
Principal Investigator: Serge de Valliere, MD Medical Outpatient Clinic, University Hospital of Lausanne
  More Information

Responsible Party: Medical Outpatient Clinic ( Serge de Vallière, MD, MSc )
Study ID Numbers: PMU-Flu
Study First Received: January 12, 2009
Last Updated: January 12, 2009
ClinicalTrials.gov Identifier: NCT00821626  
Health Authority: Switzerland: Ethikkommission

Keywords provided by University of Lausanne Hospitals:
Influenza
Rapid flu test
Returning travelers with fever

Study placed in the following topic categories:
Virus Diseases
Fever
Respiratory Tract Diseases
Respiratory Tract Infections
Influenza, Human
Orthomyxoviridae Infections

Additional relevant MeSH terms:
RNA Virus Infections

ClinicalTrials.gov processed this record on January 16, 2009